top of page
Resources > Articles
Regulatory Intelligence,
In Depth.
Articles, whitepapers, guides, and case studies for Life Sciences regulatory professionals navigating a faster, more complex regulatory world.


Separating CAPA Workflows Under QMSR: What Manufacturers Actually Need to Change
CAPA deficiencies remain one of FDA's most reliable predictors of enforcement. What separating corrective and preventive action workflows looks like under QMSR, and what manufacturers actually need to change in their quality systems.
Sep 224 min read


Complaint Handling and MDR Reporting Under QMSR: Building a System That Holds Up
How complaint handling works under the QMSR: ISO 13485 clause 8.2.2, 21 CFR 820.35 record content, Part 803 MDR timelines, Part 806, and reportability scenarios.
Sep 229 min read


FDA Just Retired the Inspection Technique It Used for Nearly 30 Years
FDA retired QSIT, its 30-year device inspection framework, on Feb 2, 2026. Here's what the new QMSR-aligned, risk-based process means for your audits.
Aug 38 min read


The Supplier You've Never Audited Is Already in Your Quality System
In February 2008, hospitals across the United States began seeing something that almost never happens with heparin, a blood thinner used in millions of procedures every year: patients going into sudden, severe allergic-type reactions — hypotension, nausea, shortness of breath — within minutes of receiving it. The FDA would eventually trace the cause to a contaminant called oversulfated chondroitin sulfate, added somewhere upstream in the crude heparin supply chain in China, a
Jul 216 min read


FDA's #1 QMSR Form 483 Audit Findings, In Its Own Words: "Risk, Risk, Risk, Risk"
Five months into FDA's new Quality Management System Regulation, the agency has said out loud what's actually showing up in QMSR Form 483 findings — and it's not a paperwork problem.
Jul 153 min read
bottom of page